Evidence map›Paper›PMID 41801184›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

G4-Ligand-Directed PROTACs Unveil DR1 as a Novel Ligand-Co-Binding G4-Protein and Reshape G4-Dependent Transcription.

Mao-Lin Li, Shu-Min Xu, Xin-Chen Jiang, Le-Tian Dai, Yu-Tao Hu, Kai-Bo Wang, Jia-Heng Tan, Zhi-Shu Huang, Shuo-Bin Chen

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mao-Lin LiGuangdong Provincial Key Laboratory of New Drug Design and Evaluation, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, China.
Shu-Min XuGuangdong Provincial Key Laboratory of New Drug Design and Evaluation, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, China.
Xin-Chen JiangGuangdong Provincial Key Laboratory of New Drug Design and Evaluation, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, China.
Le-Tian DaiGuangdong Provincial Key Laboratory of New Drug Design and Evaluation, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, China.
Yu-Tao HuGuangdong Provincial Key Laboratory of New Drug Design and Evaluation, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, China.
Kai-Bo WangState Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Bioactive Natural Product Research, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, China.
Jia-Heng TanGuangdong Provincial Key Laboratory of New Drug Design and Evaluation, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, China.
Zhi-Shu HuangGuangdong Provincial Key Laboratory of New Drug Design and Evaluation, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, China.
Shuo-Bin ChenGuangdong Provincial Key Laboratory of New Drug Design and Evaluation, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, China.ORCID https://orcid.org/0000-0001-9118-2185

Funding

Applied Basic Research Fund of Qingdao 2024A1515011751National Natural Science Foundation of Chinathe Chang Jiang Scholars Programthe Postdoctoral Fellowship Program of CPSF
6 · The paper itself

Abstract

G-quadruplexes (G4s) are dynamic nucleic acid structures whose biological impact is largely mediated by G4-binding proteins (G4BPs). While numerous G4BPs have been catalogued, the subset that specifically co-bind G4s in the presence of small-molecule ligands remains unexplored, limiting our understanding of ligand pharmacology. Here, we introduce G4-Ligand-Directed PROTACs (G4L-TACs), a chemical biology platform that couples high-affinity G4 ligands with E3 ubiquitin ligase recruiters to selectively degrade ligand-co-binding G4BPs. Using PDS-derived G4L-TACs, we identified the transcription factor DR1 as a previously unrecognized G4BP recruited to ligand-stabilized promoter G4s. G4L-TAC-mediated DR1 degradation relieved transcriptional repression at G4-rich oncogenic promoters, providing mechanistic insights into how G4 ligands influence gene expression beyond simple nucleic acid stabilization. These results establish G4L-TACs as a novel platform to discover ligand-co-binding G4BPs and reveal DR1 as a new regulatory node in G4-dependent transcription, offering a versatile tool for mechanistic dissection and therapeutic exploration.

Indexed as

DNA-Binding ProteinsG-QuadruplexesTranscription, GeneticHumansLigandsPromoter Regions, GeneticProteolysis Targeting ChimeraDNA-Binding ProteinsLigandsProteolysis Targeting ChimeraG4 binding proteinsG‐quadruplexestargeted protein degradationtranscription factor DR1

Identifiers

PMID41801184
PMCPMC13170204

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.